Syndax Pharmaceuticals (SNDX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Syndax Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$17.28-0.81(-0.04%)Pre-market

Market Cap

$1.57B

P/S

6.2x

P/B

104.2x

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

How this company scores

AverageMetricSide Score: 58/100

Strongest: Growth (21/25); weakest: Cash & Earnings Quality (10/25).

Profitability12/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality10/25

Strengths

Growing revenueInterest easily coveredCash-backed earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1323.7x5y range 38.4x – 1323.7x

P/S · 6.2x5y range 6.2x – 438.6x

Currently below its 14-quarter median.

P/B · 104.2x5y range 2.3x – 104.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.57B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $252.00M
Q. Revenue: $72.79M
TTM EBITDA: $-179.17M
TTM Op. Income: $-194.17M
Q. Op. Income: $-39.99M
TTM Net Income: $-220.76M
Q. Net Income: $-49.36M
EPS: $-0.55
Shares Out.: $88.99M

$252.00M in TTM revenue grew 222.3% YoY, reaching $72.79M last quarter. TTM EBITDA of $-179.17M and TTM operating income of $-194.17M show growth is flowing through to the bottom line. However, net income is negative at $220.76M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -48.1%
Op. Margin: -54.9%
Net Margin: -67.8%

Op. margin of -54.9% is up 127.8% YoY — cost efficiency is improving. Net margin at -67.8% Over the past year, operating margin is up 70% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.2x
P/B Ratio: 104.2x

P/S of 6.2x and P/B of 104.2x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $703.65M
Cash: $336.48M
Long-Term Debt: N/A
Book Value: $15.10M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-30.27M
TTM Free Cash Flow: $-220.83M
FCF Margin: -87.6%
FCF / Net Income: 1.0

TTM FCF of $-220.83M on $-30.27M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.